SpringerLink
Log in

Risk-adapted chemotherapy without procarbazine in treatment of children with Hodgkin lymphoma

  • Original article
  • Published:
World Journal of Pediatrics Aims and scope Submit manuscript

Abstract

Background

Because procarbazine is not available in the mainland of China, a risk-adapted chemotherapy without the drug was adopted for children with Hodgkin lymphoma (HL) in two tertiary referral centers for childhood cancer in Shanghai. The objective of the present study was to obtain the results comparable with those of previous studies.

Methods

From January 1998 to December 2009, patients below 18 years with newly diagnosed, untreated HL were enrolled in the study. The patients were stratified into risk groups R1 (early stage), R2 (intermediate stage) and R3 (advanced stage). All the patients who had attained a complete remission were not given involved field radiotherapy.

Results

Fifty-six patients were eligible for the study. The 4-year event-free survival (EFS) rate was 100%, 80.3%±7.2%, and 62.5%±12.1% for the risk groups R1, R2, and R3, respectively. There was statistically significant difference in EFS between patients with and those without B symptoms (P<0.001). In group R2, the EFS rate was higher for patients treated with chemotherapy combined with radiation (100% vs. 75%±8.8%). But no statistical difference was observed (P=0.177). At the time of evaluation (December 31, 2010), secondary malignancy was not observed.

Conclusions

A significant fraction of children with early stage or intermediate stage HL can be cured with a chemotherapy regimen without procarbazine. Complete response to chemotherapy seems not to be a determinant to omit radiotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Canada)

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Liang RHS, Yau CC, Muckaden MA, Dinshaw KA, Todd D. Hodgkin’s disease in Asia. In: Mauch PM, Armitage JO, Diehl V, Hoppe RT, Weiss LM, eds. Hodgkin’s Disease. Philadelphia: Lippincott Williams & Williams, 1999: 771–780.

    Google Scholar 

  2. Bao PP, Zheng Y, Wang CF, Gu K, ** F, Lu W. Time trends and characteristics of childhood cancer among children age 0–14 in Shanghai. Pediatr Blood Cancer 2009;53:13–16.

    Article  PubMed  Google Scholar 

  3. Nachman JB, Sposto R, Herzog P, Gilchrist GS, Wolden SL, Thomson J, et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin’s disease who achieve a complete response to chemotherapy. J Clin Oncol 2002;20:3765–3771.

    Article  PubMed  Google Scholar 

  4. Lukes R, Butler J. The pathology and nomenclature of Hodgkin’s disease. Cancer Res 1966;26:1063–1083.

    PubMed  CAS  Google Scholar 

  5. Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswald meeting. J Clin Oncol 1989;7:1630–1636.

    PubMed  CAS  Google Scholar 

  6. Schwartz CL. The management of Hodgkin disease in the young child. Curr Opin Pediar 2003;15:10–16.

    Article  Google Scholar 

  7. Hochberg J, Waxman IM, Kelly KM, Morris E, Cairo MS. Adolescent non-Hodgkin lymphoma and Hodgkin lymphoma state of the science. Br J Haematol 2009;144:24–40.

    Article  PubMed  Google Scholar 

  8. Landman-Parker J, Pacquement H, Leblanc T, Habrand JL, Terrier-Lacombe MJ, Bertrand Y, et al. Localized childhood Hodgkin’s disease: response-adapted chemotherapy with etoposide, bleomycin, vinblastine, and prednisone before lowdose radiation therapy-results of the French Society of Pediatric Oncology Study MDH90. J Clin Oncol 2000;18:1500–1507.

    PubMed  CAS  Google Scholar 

  9. Dorffel W, Luders H, Ruhl U, Albrecht M, Marciniak H, Parwaresch R, et al. Preliminary results of the multicenter trial GPOH-HD 95 for the treatment of Hodgkin’s disease in children and adolescents: analysis and outlook. Klin Padiatr 2003;215: 139–145.

    Article  PubMed  CAS  Google Scholar 

  10. Kung FH, Schwartz CL, Ferree CR, London WB, Ternberg JL, Behm FG, et al. POG8625: a randomized trial comparing chemotherapy with chemoradiotherapy for children and adolescents with stages I, IIA, IIIA1 Hodgkin disease: a report from the Children’s Oncology Group. J Pediatr Hematol Oncol 2006;28:362–368.

    Article  PubMed  CAS  Google Scholar 

  11. Donaldson SS, Link MP, Weinstein HJ, Rai SN, Brain S, Billett AL, et al. Final results of a prospective clinical trial with VAMP and low-dose involved field radiation for children with low-risk Hodgkin’s disease. J Clin Oncol 2007;25:332–337.

    Article  PubMed  CAS  Google Scholar 

  12. Schellong G, Brämswig JH, Hörnig-Franz I, Schwarze EW, Pötter R, Wannenmacher M. Hodgkin’s disease in children: combined modality treatment for stages IA, IIB, and IIA. Results in 356 patients of German/Austrian Pediatric Study Group. Ann Oncol 1994;5(Suppl 2):113–115.

    Article  PubMed  Google Scholar 

  13. Weiner MA, Leventhal B, Brecher ML, Marcus RB, Cantor A, Gieser PW, et al. Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin’s disease in pediatric patients: a Pediatric Oncology Group study. J Clin Oncol 1997;15:2769–2779.

    PubMed  CAS  Google Scholar 

  14. Hudson MM, Krasin M, Link MP, Donaldson SS, Billups C, Merchant TE, et al. Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin’s disease. J Clin Oncol 2004;22:4541–4550.

    Article  PubMed  CAS  Google Scholar 

  15. Rühl U, Albrecht M, Dieckmann K, Lüders H, Marciniak H, Schellenberg D, et al. Response-adapted radiotherapy in the treatment of pediatric Hodgkin’s disease: an interim report at 5 years of the German GPOH-HD95 trial. Int J Radiat Oncol Biol Phys 2001;51:1209–1218.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Children’s Hospital, Shanghai Medical College, Fudan University, Shanghai, China

    Yi-** Gao & Feng-Juan Lu

  2. Shanghai Children’s Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

    **g-Yan Tang, Ci Pan, Hui-Liang Xue & **g Chen

  3. Shanghai Children’s Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China

    **g-Yan Tang

Authors
  1. Yi-** Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. **g-Yan Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ci Pan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Feng-Juan Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hui-Liang Xue
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. **g Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to **g-Yan Tang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gao, YJ., Tang, JY., Pan, C. et al. Risk-adapted chemotherapy without procarbazine in treatment of children with Hodgkin lymphoma. World J Pediatr 9, 32–35 (2013). https://doi.org/10.1007/s12519-012-0390-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12519-012-0390-0

Key words

Search

Navigation